Navamedic ASA (NAVA)

Currency in NOK
14.30
-0.35(-2.39%)
Closed·
Trading near 52-week Low
NAVA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
14.2014.95
52 wk Range
14.2026.50
Key Statistics
Prev. Close
14.65
Open
14.55
Day's Range
14.2-14.95
52 wk Range
14.2-26.5
Volume
44.98K
Average Volume (3m)
32.86K
1-Year Change
-35%
Book Value / Share
12.76
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NAVA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
21.00
Upside
+46.85%
Members' Sentiments
Bearish
Bullish
ProTips
Trading near 52-week low

Navamedic ASA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 21.00
(+46.85% Upside)

Navamedic ASA Earnings Call Summary for Q2/2026

  • Q2 revenue rose 2.2% to NOK 140.3M; adjusted EBITDA surged 57% to NOK 15.9M with margin expanding 380 bps to 11.3% year-over-year.
  • Prescription drugs segment grew 8.9% led by Mysimba recovery; consumer health fell 7.0% as Modifast declined 14% amid competitive pressure.
  • Management maintained flat full-year 2026 revenue guidance at 2025 levels but expects continued margin improvement from product mix optimization.
  • New CEO Lars Minor emphasized profitable growth strategy; company launched Viruno in Sweden/Finland and preparing Flexilev for 2027 European rollout.
  • Shares fell 3.06% to $17.40 as investors weighed strong profitability gains against modest growth outlook and NOK 5.3M inventory write-off.
Last Updated: 2026-08-14, 03:04 a/m
Read Full Transcript

Earnings

Latest Release
Aug 14, 2026
EPS / Forecast
-0.02 / --
Revenue / Forecast
146.45M / 145M
EPS Revisions
Last 90 days

NAVA Income Statement

Compare NAVA to Peers and Sector

Metrics to compare
NAVA
Peers
Sector
Relationship
P/E Ratio
−15.3x5.6x−0.4x
PEG Ratio
−0.340.010.00
Price/Book
1.2x2.4x2.6x
Price / LTM Sales
0.6x2.0x3.1x
Upside (Analyst Target)
44.3%41.8%46.0%
Fair Value Upside
Unlock31.7%5.3%Unlock

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. Its product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. The company offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases, fat metabolism, renal, nutritional support, and ketogenic diet. In addition, it provides consumer health products consisting of non-prescription drugs and health care products for erectile dysfunction, pain, gastro-related problems, and others primarily through pharmacies and drugstores; prescription medicines covering obesity, Parkinson’s disease, urology, and cardiology; and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was founded in 2002 and is headquartered in Oslo, Norway.

Employees
38
Market
Norway

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.27M5.28%18.55M
Other Institutional Investors
16.95M70.66%248.25M
Public Companies & Retail Investors
5.77M24.06%84.53M
Total
23.98M100.00%351.33M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Kistefos A.S.30.91%7,413,195108,603
Skandinaviska Enskilda Banken AB (publ)24.38%5,845,62485,638

People Also Watch

35.78
ELISA
-1.32%
6.43
MANTA
+0.63%
6.220
REACH
+1.30%
0.650
ENSU
-1.52%
54.40
BWE
-0.37%

FAQ

What Is the Navamedic (NAVA) Stock Price Today?

The Navamedic stock price today is 14.30 NOK.

What Stock Exchange Does Navamedic Trade On?

Navamedic is listed and trades on the Oslo Stock Exchange.

What Is the Stock Symbol for Navamedic?

The stock symbol for Navamedic is "NAVA."

What Is the Navamedic Market Cap?

As of today, Navamedic market cap is 351.33M NOK.

What Is Navamedic's Earnings Per Share (TTM)?

The Navamedic EPS (TTM) is -1.04.

When Is the Next Navamedic Earnings Date?

Navamedic will release its next earnings report on Oct 29, 2026.

From a Technical Analysis Perspective, Is NAVA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Navamedic Stock Split?

Navamedic has split 1 times.

How Many Employees Does Navamedic Have?

Navamedic has 38 employees.

What is the current trading status of Navamedic (NAVA)?

As of Aug 27, 2026, Navamedic (NAVA) is trading at a price of 14.30 NOK, with a previous close of 14.65 NOK. The stock has fluctuated within a day range of 14.20 NOK to 14.95 NOK, while its 52-week range spans from 14.20 NOK to 26.50 NOK.

What Is Navamedic (NAVA) Price Target According to Analysts?

The average 12-month price target for Navamedic is 21.00 NOK, with a high estimate of 21 NOK and a low estimate of 21 NOK. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +46.85% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.